Wednesday, February 10, 2010, 10:24pm SGT - The Singapore stock market is closed.
To create a watchlist or portfolio of shares, Register
FINANCE HOME PAGEINVESTINGFINANCE NEWS
    Market:       |  

Aastrom Biosciences, Inc. (ASTM)

At 4:59AM SGT: 0.1819 USD   0.00 (0.00%)  
 MORE ON ASTM 
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
 Aastrom Biosciences, Inc. (NCM:ASTM) Delayed quote dataEdit
Pre-Market: 0.18 Down 0.0019 (1.04%) as of 10:01pm SGT on 02/10/10
Last Trade:0.1819 USD
Trade Time:4:59AM SGT
Change: 0.00 (0.00%)
Prev Close:0.1819
Open:N/A
Bid:0.173 x 5000
Ask:0.19 x 2000
1y Target Est:0.50
Day's Range:N/A - N/A
52wk Range:0.17 - 0.63
Volume:8,000
Avg Vol (3m):2,913,400
Market Cap:31.65M
P/E (ttm):N/A
EPS (ttm):-0.105
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
Use Y! Toolbar to track stocks
 Add ASTM to Portfolio   Download Data

 HEADLINES 
•Aastrom Reports Second Quarter Fiscal Year 2010 Financial Results
GlobeNewswire (Wed 9:30pm)
•AASTROM BIOSCIENCES INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financia
EDGAR Online (Tue 10:09pm)
•Aastrom Announces One-for-Eight Reverse Stock Split
GlobeNewswire (Tue 9:30pm)
•AASTROM BIOSCIENCES INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhi
EDGAR Online (Thu, Jan 28)
•Q+A-Skin cells transformed directly to nerve in study
at Reuters (Thu, Jan 28)
•Biotech Stock Alert for Aastrom Biosciences Inc. Issued by InvestorSoup
GlobeNewswire (Mon, Jan 25)
•Aastrom Biosciences Announces Closing of Unit Offering
GlobeNewswire (Fri, Jan 22)
•Skymark Research Initiates Independent Research Coverage On Aastrom Biosciences, Inc.
GlobeNewswire (Tue, Jan 19)
•AASTROM BIOSCIENCES INC Files SEC form 8-K, Entry into a Material Definitive Agreement
EDGAR Online (Sat, Jan 16)
•Aastrom, Broadwind Energy: Late Day Volume Plays
at TheStreet.com (Sat, Jan 16)
More Headlines for ASTM...
 ANALYST 
EPS Est (next year) (Jun-10) :N/A
EPS Est (in 2 years) (Jun-11) :N/A
Avg Rec (current)*:3.0
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
Aastrom Biosciences, Inc. engages in developing autologous cell products for the treatment of severe, chronic, and cardiovascular diseases. The company's proprietary tissue repair cell (TRC) technology expands the numbers of stem and early pr...

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Search by Company
•Latest News•Singapore Indices